Anna A.
Anna A. Henry, Kansas City, MO US
Patent application number | Description | Published |
---|---|---|
20150122861 | GARMENT WITH COMPRESSION CONCEALMENT COMPARTMENT - A compression concealment compartment for concealing an article between a portion of a garment and a body of a wearer includes a concealment panel having a peripheral edge. The concealment panel has at least two layers and includes an outer panel constructed of a first material having at least one of a weight and a drape configured to reduce a silhouette of an article and having a peripheral edge. An inner panel is constructed of a second material and is joined to the outer panel along a portion of the peripheral edge, wherein together they define the peripheral edge of the concealment panel. A liner has an outer surface in opposed relationship with the inner surface of the inner panel, and an inner surface for facing the body of the wearer. The liner is joined to the concealment panel along a portion of the peripheral edge to define the compartment having an interior space for containing the article. | 05-07-2015 |
Anna A. Kulidjian, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20140304844 | XENOGRAFT MODEL OF HUMAN BONE METASTATIC PROSTATE CANCER - The disclosure herein provides a bone metastasis-derived prostate cancer xenograft model. The disclosure also provides methods for making a bone metastasis-derived prostate cancer xenograft model. In alternative embodiments, the disclosure provides compositions and methods for testing whether a drug, compound, diet, therapy or treatment is effective or efficacious for preventing, ameliorating, slowing the progress of, stopping or slowing the metastasis of, or for causing a full or partial remission of, a cancer, or a prostate cancer, or a human prostate cancer. The disclosure provides compositions and methods whether a drug, compound, diet, therapy or treatment is effective or efficacious for modifying or effecting the structure or organization or vascularization of a tumor microenvironment; or effects the growth, survival, phenotype or histology (tissue or organ structure or microenvironments) of connective tissue, bone cells, osteoblasts, osteocytes, osteoclasts, bone marrow cells, fibroblasts or angiogenic cells. | 10-09-2014 |
Anna A. Magaeva, Tomsk RU
Patent application number | Description | Published |
---|---|---|
20140186268 | Oxide Ferrimagnetics with Spinel Structure Nanoparticles and Iron Oxide Nanoparticles, Biocompatible Aqueous Colloidal Systems Comprising Nanoparticles, Ferriliposomes, and Uses Thereof - The present invention relates to methods for producing oxide ferrimagnetics with spinel structure and iron oxide nanoparticles by soft mechanochemical synthesis using inorganic salt hydrates, oxide ferrimagnetics with spinel structure and iron oxide nanoparticles of ultra-small size and high specific surface area obtainable by the methods, biocompatible aqueous colloidal systems comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, carriers comprising oxide ferrimagnetics with spinel structure and iron oxide nanoparticles, and uses thereof in medicine. | 07-03-2014 |
Anna A. Michrowska, Warsaw PL
Patent application number | Description | Published |
---|---|---|
20080319199 | Preparation of Catalysts - The present invention discloses a novel synthesis method for a catalyst of formula 6, wherein Mes has the meaning of mesityl. | 12-25-2008 |
Anna A. Pimenova, St-Petersburg RU
Patent application number | Description | Published |
---|---|---|
20110059116 | LASER-BASED VACCINE ADJUVANTS - The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine. | 03-10-2011 |
20130078265 | LASER-BASED VACCINE ADJUVANTS - The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine. | 03-28-2013 |
20140335110 | LASER-BASED VACCINE ADJUVANTS - The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine. | 11-13-2014 |
Anna A. Sablina, Kessel-Lo BE
Patent application number | Description | Published |
---|---|---|
20110306057 | Phosphorylated RalA - Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods. | 12-15-2011 |
Anna A. Tourovskaia, Mountlake Terrace, WA US
Patent application number | Description | Published |
---|---|---|
20150240194 | Microfluidic System for Reproducing Functional Units of Tissues and Organs In Vitro - A microfluidic system for generating compartmentalized microenvironments of tissues and organs in vitro and for independently perfusing the compartments. A microfluidic device that includes at least a first perfusion path and a second separate perfusion path. The microfluidic device also has a chamber containing a matrix, where the matrix surrounds at least one void whose lumen is in fluidic connection exclusively with the first perfusion path, where the at least one void can be populated with at least one cell type in such way that the cells are in direct contact with the matrix and the matrix is in fluidic connection exclusively with the second separate perfusion path. | 08-27-2015 |
Anna A. Zabierek, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20110166129 | INHIBITORS OF JANUS KINASES - The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer. | 07-07-2011 |
Anna A. Zabierek, Salem, MA US
Patent application number | Description | Published |
---|---|---|
20100216796 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives in vivo. | 08-26-2010 |
Anna A. Zabierek, East Kingston, NH US
Patent application number | Description | Published |
---|---|---|
20090209566 | Spirocyclic Compounds - The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR | 08-20-2009 |
20110098268 | SPIROCYCLIC COMPOUNDS - The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 04-28-2011 |